www.fdanews.com/articles/139462-sunovion-pharmaceuticals-canada-announces-health-canada-acceptance-of-lurasidone-new-drug-submission-for-treatment-of-schizophrenia
Sunovion Pharmaceuticals Canada Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia
August 23, 2011
Sunovion Pharmaceuticals Canada announced a new drug submission for Lurasidone HCl, to treat adult patients with schizophrenia, has been accepted for review by Health Canada.
Digital Journal
Digital Journal